Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Editorial: accelerated infliximab induction-it's time to settle the debate! Authors' reply.

Sebastian S, Kennedy NA, Subramanian S, Raine T.

Aliment Pharmacol Ther. 2019 Nov;50(9):1061-1062. doi: 10.1111/apt.15498. No abstract available.

PMID:
31625193
2.

HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease.

Sazonovs A, Kennedy NA, Moutsianas L, Heap GA, Rice DL, Reppell M, Bewshea CM, Chanchlani N, Walker GJ, Perry MH, McDonald TJ, Lees CW, Cummings JRF, Parkes M, Mansfield JC, Barrett JC, McGovern D, Goodhand JR, Anderson CA, Ahmad T; PANTS consortium.

Gastroenterology. 2019 Oct 5. pii: S0016-5085(19)41414-5. doi: 10.1053/j.gastro.2019.09.041. [Epub ahead of print]

PMID:
31600487
3.

British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H; IBD guidelines eDelphi consensus group, Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB.

Gut. 2019 Sep 27. pii: gutjnl-2019-318484. doi: 10.1136/gutjnl-2019-318484. [Epub ahead of print]

4.

Infliximab induction regimens in steroid-refractory acute severe colitis: a multicentre retrospective cohort study with propensity score analysis.

Sebastian S, Myers S, Argyriou K, Martin G, Los L, Fiske J, Ranjan R, Cooper B, Goodoory V, Ching HL, Jayasooriya N, Brooks J, Dhar A, Shenoy AH, Limdi JK, Butterworth J, Allen PB, Samuel S, Moran GW, Shenderey R, Parkes G, Lobo A, Kennedy NA, Subramanian S, Raine T.

Aliment Pharmacol Ther. 2019 Sep;50(6):675-683. doi: 10.1111/apt.15456.

PMID:
31456297
5.

Reply.

Kennedy NA, Lees CW.

Clin Gastroenterol Hepatol. 2019 Jul 24. pii: S1542-3565(19)30775-X. doi: 10.1016/j.cgh.2019.07.031. [Epub ahead of print] No abstract available.

PMID:
31351132
6.

Factors associated with depression in people with inflammatory bowel disease: The relationship between active disease and biases in neurocognitive processing.

Wilkinson B, Trick L, Knight A, Valton V, Goodhand J, Kennedy NA, Heerasing N, Ahmad T, Bland A, Elliott R, Roiser JP, Dickens C.

Neurogastroenterol Motil. 2019 Aug;31(8):e13647. doi: 10.1111/nmo.13647. Epub 2019 Jul 2.

PMID:
31267614
7.

Genome-wide association study of microscopic colitis in the UK Biobank confirms immune-related pathogenesis.

Green HD, Beaumont RN, Thomas A, Hamilton B, Wood AR, Sharp S, Jones SE, Tyrrell J, Walker G, Goodhand J, Kennedy NA, Ahmad T, Weedon MN.

J Crohns Colitis. 2019 May 24. pii: jjz104. doi: 10.1093/ecco-jcc/jjz104. [Epub ahead of print]

PMID:
31125052
8.

Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.

Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, Thomas A, Nice R, Perry MH, Bouri S, Chanchlani N, Heerasing NM, Hendy P, Lin S, Gaya DR, Cummings JRF, Selinger CP, Lees CW, Hart AL, Parkes M, Sebastian S, Mansfield JC, Irving PM, Lindsay J, Russell RK, McDonald TJ, McGovern D, Goodhand JR, Ahmad T; UK Inflammatory Bowel Disease Pharmacogenetics Study Group.

Lancet Gastroenterol Hepatol. 2019 May;4(5):341-353. doi: 10.1016/S2468-1253(19)30012-3. Epub 2019 Feb 27.

PMID:
30824404
9.

Photoacoustic Imaging for Image-guided Endovenous Laser Ablation Procedures.

Yan Y, John S, Ghalehnovi M, Kabbani L, Kennedy NA, Mehrmohammadi M.

Sci Rep. 2019 Feb 27;9(1):2933. doi: 10.1038/s41598-018-37588-2.

10.

Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease.

Walker GJ, Harrison JW, Heap GA, Voskuil MD, Andersen V, Anderson CA, Ananthakrishnan AN, Barrett JC, Beaugerie L, Bewshea CM, Cole AT, Cummings FR, Daly MJ, Ellul P, Fedorak RN, Festen EAM, Florin TH, Gaya DR, Halfvarson J, Hart AL, Heerasing NM, Hendy P, Irving PM, Jones SE, Koskela J, Lindsay JO, Mansfield JC, McGovern D, Parkes M, Pollok RCG, Ramakrishnan S, Rampton DS, Rivas MA, Russell RK, Schultz M, Sebastian S, Seksik P, Singh A, So K, Sokol H, Subramaniam K, Todd A, Annese V, Weersma RK, Xavier R, Ward R, Weedon MN, Goodhand JR, Kennedy NA, Ahmad T; IBD Pharmacogenetics Study Group.

JAMA. 2019 Feb 26;321(8):773-785. doi: 10.1001/jama.2019.0709. Erratum in: JAMA. 2019 Apr 23;321(16):1636.

11.

Association Between Level of Fecal Calprotectin and Progression of Crohn's Disease.

Kennedy NA, Jones GR, Plevris N, Patenden R, Arnott ID, Lees CW.

Clin Gastroenterol Hepatol. 2019 Oct;17(11):2269-2276.e4. doi: 10.1016/j.cgh.2019.02.017. Epub 2019 Feb 14.

12.

Faecal Calprotectin and Magnetic Resonance Enterography in Ileal Crohn's Disease: Correlations Between Disease Activity and Long-Term Follow-Up.

Jones GR, Fascì-Spurio F, Kennedy NA, Plevris N, Jenkinson P, Lyons M, Wong L, MacLean P, Glancy S, Lees CW.

J Crohns Colitis. 2019 Mar 30;13(4):442-450. doi: 10.1093/ecco-jcc/jjy187.

PMID:
30452618
13.

Promoter methylation of the MGAT3 and BACH2 genes correlates with the composition of the immunoglobulin G glycome in inflammatory bowel disease.

Klasić M, Markulin D, Vojta A, Samaržija I, Biruš I, Dobrinić P, Ventham NT, Trbojević-Akmačić I, Šimurina M, Štambuk J, Razdorov G, Kennedy NA, Satsangi J, Dias AM, Pinho S, Annese V, Latiano A, D'Inca R; IBD consortium, Lauc G, Zoldoš V.

Clin Epigenetics. 2018 Jun 4;10:75. doi: 10.1186/s13148-018-0507-y. eCollection 2018.

14.

Faecal calprotectin effectively excludes inflammatory bowel disease in 789 symptomatic young adults with/without alarm symptoms: a prospective UK primary care cohort study.

Walker GJ, Moore L, Heerasing N, Hendy P, Perry MH, McDonald TJ, Debenham T, Bethune R, Bewshea C, Hyde C, Heap GA, Singh A, Calvert C, Kennedy NA, Goodhand JR, Ahmad T.

Aliment Pharmacol Ther. 2018 Apr;47(8):1103-1116. doi: 10.1111/apt.14563. Epub 2018 Mar 5.

15.

The Impact of NOD2 Variants on Fecal Microbiota in Crohn's Disease and Controls Without Gastrointestinal Disease.

Kennedy NA, Lamb CA, Berry SH, Walker AW, Mansfield J, Parkes M, Simpkins R, Tremelling M, Nutland S; UK IBD Genetics Consortium, Parkhill J, Probert C, Hold GL, Lees CW.

Inflamm Bowel Dis. 2018 Feb 15;24(3):583-592. doi: 10.1093/ibd/izx061.

16.

Glycosylation of Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel Diseases.

Šimurina M, de Haan N, Vučković F, Kennedy NA, Štambuk J, Falck D, Trbojević-Akmačić I, Clerc F, Razdorov G, Khon A, Latiano A, D'Incà R, Danese S, Targan S, Landers C, Dubinsky M; Inflammatory Bowel Disease Biomarkers Consortium, McGovern DPB, Annese V, Wuhrer M, Lauc G.

Gastroenterology. 2018 Apr;154(5):1320-1333.e10. doi: 10.1053/j.gastro.2018.01.002. Epub 2018 Jan 6.

17.

Colonoscopy quality with Entonox®vs intravenous conscious sedation: 18608 colonoscopy retrospective study.

Robertson AR, Kennedy NA, Robertson JA, Church NI, Noble CL.

World J Gastrointest Endosc. 2017 Sep 16;9(9):471-479. doi: 10.4253/wjge.v9.i9.471.

18.
19.

Interaction Between NOD2 and Smoking in the Pathogenesis of Crohn's Disease.

Heerasing N, Kennedy NA.

EBioMedicine. 2017 Jul;21:49-50. doi: 10.1016/j.ebiom.2017.06.016. Epub 2017 Jun 19. Review. No abstract available.

20.

Editorial: which iron preparation for patients with IBD?

Kennedy NA, Goodhand JR, Rampton DS.

Aliment Pharmacol Ther. 2017 Jul;46(2):194-195. doi: 10.1111/apt.14105. No abstract available.

21.

Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial.

Mowat C, Arnott I, Cahill A, Smith M, Ahmad T, Subramanian S, Travis S, Morris J, Hamlin J, Dhar A, Nwokolo C, Edwards C, Creed T, Bloom S, Yousif M, Thomas L, Campbell S, Lewis SJ, Sebastian S, Sen S, Lal S, Hawkey C, Murray C, Cummings F, Goh J, Lindsay JO, Arebi N, Potts L, McKinley AJ, Thomson JM, Todd JA, Collie M, Dunlop MG, Mowat A, Gaya DR, Winter J, Naismith GD, Ennis H, Keerie C, Lewis S, Prescott RJ, Kennedy NA, Satsangi J; TOPPIC Study Group.

Lancet Gastroenterol Hepatol. 2016 Dec;1(4):273-282. doi: 10.1016/S2468-1253(16)30078-4. Epub 2016 Aug 30.

22.

A plea for TDM-based optimisation for treatment of Crohn's disease - Authors' reply.

Kennedy NA, Keerie C, Mowat C, Satsangi J.

Lancet Gastroenterol Hepatol. 2017 Feb;2(2):81-82. doi: 10.1016/S2468-1253(16)30222-9. Epub 2017 Jan 12. No abstract available.

PMID:
28403991
23.

MDR1 deficiency impairs mitochondrial homeostasis and promotes intestinal inflammation.

Ho GT, Aird RE, Liu B, Boyapati RK, Kennedy NA, Dorward DA, Noble CL, Shimizu T, Carter RN, Chew ETS, Morton NM, Rossi AG, Sartor RB, Iredale JP, Satsangi J.

Mucosal Immunol. 2018 Jan;11(1):120-130. doi: 10.1038/mi.2017.31. Epub 2017 Apr 12.

24.

Exclusive enteral nutrition provides an effective bridge to safer interval elective surgery for adults with Crohn's disease.

Heerasing N, Thompson B, Hendy P, Heap GA, Walker G, Bethune R, Mansfield S, Calvert C, Kennedy NA, Ahmad T, Goodhand JR.

Aliment Pharmacol Ther. 2017 Mar;45(5):660-669. doi: 10.1111/apt.13934. Epub 2017 Jan 20.

25.

Exploring the genetic architecture of inflammatory bowel disease by whole-genome sequencing identifies association at ADCY7.

Luo Y, de Lange KM, Jostins L, Moutsianas L, Randall J, Kennedy NA, Lamb CA, McCarthy S, Ahmad T, Edwards C, Serra EG, Hart A, Hawkey C, Mansfield JC, Mowat C, Newman WG, Nichols S, Pollard M, Satsangi J, Simmons A, Tremelling M, Uhlig H, Wilson DC, Lee JC, Prescott NJ, Lees CW, Mathew CG, Parkes M, Barrett JC, Anderson CA.

Nat Genet. 2017 Feb;49(2):186-192. doi: 10.1038/ng.3761. Epub 2017 Jan 9.

26.

Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease.

de Lange KM, Moutsianas L, Lee JC, Lamb CA, Luo Y, Kennedy NA, Jostins L, Rice DL, Gutierrez-Achury J, Ji SG, Heap G, Nimmo ER, Edwards C, Henderson P, Mowat C, Sanderson J, Satsangi J, Simmons A, Wilson DC, Tremelling M, Hart A, Mathew CG, Newman WG, Parkes M, Lees CW, Uhlig H, Hawkey C, Prescott NJ, Ahmad T, Mansfield JC, Anderson CA, Barrett JC.

Nat Genet. 2017 Feb;49(2):256-261. doi: 10.1038/ng.3760. Epub 2017 Jan 9.

27.

Integrative epigenome-wide analysis demonstrates that DNA methylation may mediate genetic risk in inflammatory bowel disease.

Ventham NT, Kennedy NA, Adams AT, Kalla R, Heath S, O'Leary KR, Drummond H; IBD BIOM consortium; IBD CHARACTER consortium, Wilson DC, Gut IG, Nimmo ER, Satsangi J.

Nat Commun. 2016 Nov 25;7:13507. doi: 10.1038/ncomms13507.

28.

Serum Calprotectin: A Novel Diagnostic and Prognostic Marker in Inflammatory Bowel Diseases.

Kalla R, Kennedy NA, Ventham NT, Boyapati RK, Adams AT, Nimmo ER, Visconti MR, Drummond H, Ho GT, Pattenden RJ, Wilson DC, Satsangi J.

Am J Gastroenterol. 2016 Dec;111(12):1796-1805. doi: 10.1038/ajg.2016.342. Epub 2016 Sep 6.

PMID:
27596694
29.

Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis.

Kennedy NA, Warner B, Johnston EL, Flanders L, Hendy P, Ding NS, Harris R, Fadra AS, Basquill C, Lamb CA, Cameron FL, Murray CD, Parkes M, Gooding I, Ahmad T, Gaya DR, Mann S, Lindsay JO, Gordon J, Satsangi J, Hart A, McCartney S, Irving P; UK Anti-TNF withdrawal study group, Lees CW.

Aliment Pharmacol Ther. 2016 Apr;43(8):910-923. doi: 10.1111/apt.13547. Epub 2016 Feb 19. Review.

30.

DNA methylation in a Scottish family multiply affected by bipolar disorder and major depressive disorder.

Walker RM, Christoforou AN, McCartney DL, Morris SW, Kennedy NA, Morten P, Anderson SM, Torrance HS, Macdonald A, Sussmann JE, Whalley HC, Blackwood DH, McIntosh AM, Porteous DJ, Evans KL.

Clin Epigenetics. 2016 Jan 20;8:5. doi: 10.1186/s13148-016-0171-z. eCollection 2016.

31.

Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study.

Cleynen I, Boucher G, Jostins L, Schumm LP, Zeissig S, Ahmad T, Andersen V, Andrews JM, Annese V, Brand S, Brant SR, Cho JH, Daly MJ, Dubinsky M, Duerr RH, Ferguson LR, Franke A, Gearry RB, Goyette P, Hakonarson H, Halfvarson J, Hov JR, Huang H, Kennedy NA, Kupcinskas L, Lawrance IC, Lee JC, Satsangi J, Schreiber S, Théâtre E, van der Meulen-de Jong AE, Weersma RK, Wilson DC; International Inflammatory Bowel Disease Genetics Consortium, Parkes M, Vermeire S, Rioux JD, Mansfield J, Silverberg MS, Radford-Smith G, McGovern DP, Barrett JC, Lees CW.

Lancet. 2016 Jan 9;387(10014):156-67. doi: 10.1016/S0140-6736(15)00465-1. Epub 2015 Oct 18.

32.

Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease.

Torres J, Boyapati RK, Kennedy NA, Louis E, Colombel JF, Satsangi J.

Gastroenterology. 2015 Dec;149(7):1716-30. doi: 10.1053/j.gastro.2015.08.055. Epub 2015 Sep 14. Review.

33.

Correction: changes to serum sample tube and processing methodology does not cause inter-individual variation in automated whole serum N-glycan profiling in health and disease.

Ventham NT, Gardner RA, Kennedy NA, Shubhakar A, Kalla R, Nimmo ER; IBD-BIOM Consortium, Fernandes DL, Satsangi J, Spencer DI.

PLoS One. 2015 Jun 1;10(6):e0129335. doi: 10.1371/journal.pone.0129335. eCollection 2015. No abstract available.

34.

MicroRNAs: new players in inflammatory bowel disease.

Kalla R, Ventham NT, Kennedy NA.

Gut. 2015 Jun;64(6):1008. doi: 10.1136/gut.2014.307891corr1. No abstract available.

35.

Inflammatory bowel disease associates with proinflammatory potential of the immunoglobulin G glycome.

Trbojević Akmačić I, Ventham NT, Theodoratou E, Vučković F, Kennedy NA, Krištić J, Nimmo ER, Kalla R, Drummond H, Štambuk J, Dunlop MG, Novokmet M, Aulchenko Y, Gornik O, Campbell H, Pučić Baković M, Satsangi J, Lauc G; IBD-BIOM Consortium.

Inflamm Bowel Dis. 2015 Jun;21(6):1237-47. doi: 10.1097/MIB.0000000000000372.

36.

Changes to serum sample tube and processing methodology does not cause Intra-Individual [corrected] variation in automated whole serum N-glycan profiling in health and disease.

Ventham NT, Gardner RA, Kennedy NA, Shubhakar A, Kalla R, Nimmo ER; IBD-BIOM Consortium, Fernandes DL, Satsangi J, Spencer DI.

PLoS One. 2015 Apr 1;10(4):e0123028. doi: 10.1371/journal.pone.0123028. eCollection 2015. Erratum in: PLoS One. 2015;10(6):e0129335.

37.

Serum C-reactive protein and CRP genotype in pediatric inflammatory bowel disease: influence on phenotype, natural history, and response to therapy.

Henderson P, Kennedy NA, Van Limbergen JE, Cameron FL, Satsangi J, Russell RK, Wilson DC.

Inflamm Bowel Dis. 2015 Mar;21(3):596-605. doi: 10.1097/MIB.0000000000000296.

PMID:
25636121
38.

Predicting outcomes in acute severe ulcerative colitis.

Ventham NT, Kalla R, Kennedy NA, Satsangi J, Arnott ID.

Expert Rev Gastroenterol Hepatol. 2015 Apr;9(4):405-15. doi: 10.1586/17474124.2015.992880. Epub 2014 Dec 15. Review.

PMID:
25494666
39.

MicroRNAs: new players in IBD.

Kalla R, Ventham NT, Kennedy NA, Quintana JF, Nimmo ER, Buck AH, Satsangi J.

Gut. 2015 Mar;64(3):504-17. doi: 10.1136/gutjnl-2014-307891. Epub 2014 Dec 4. Review. Erratum in: Gut. 2015 Jun;64(6):1008.

40.

Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients.

Kennedy NA, Kalla R, Warner B, Gambles CJ, Musy R, Reynolds S, Dattani R, Nayee H, Felwick R, Harris R, Marriott S, Senanayake SM, Lamb CA, Al-Hilou H, Gaya DR, Irving PM, Mansfield J, Parkes M, Ahmad T, Cummings JR, Arnott ID, Satsangi J, Lobo AJ, Smith M, Lindsay JO, Lees CW.

Aliment Pharmacol Ther. 2014 Dec;40(11-12):1313-23. doi: 10.1111/apt.12980. Epub 2014 Oct 6.

41.

Nationwide linkage analysis in Scotland-Has mortality following hospital admission for Crohn's disease changed in the early 21st century?

Ventham NT, Kennedy NA, Duffy A, Clark DN, Crowe AM, Knight AD, Nicholls RJ, Satsangi J.

J Crohns Colitis. 2014 Sep 26. pii: S1873-9946(14)00267-0. doi: 10.1016/j.crohns.2014.09.002. [Epub ahead of print]

PMID:
25267174
42.

Two-stage genome-wide methylation profiling in childhood-onset Crohn's Disease implicates epigenetic alterations at the VMP1/MIR21 and HLA loci.

Adams AT, Kennedy NA, Hansen R, Ventham NT, OʼLeary KR, Drummond HE, Noble CL, El-Omar E, Russell RK, Wilson DC, Nimmo ER, Hold GL, Satsangi J.

Inflamm Bowel Dis. 2014 Oct;20(10):1784-93. doi: 10.1097/MIB.0000000000000179.

43.

Clinical utility and diagnostic accuracy of faecal calprotectin for IBD at first presentation to gastroenterology services in adults aged 16-50 years.

Kennedy NA, Clark A, Walkden A, Chang JC, Fascí-Spurio F, Muscat M, Gordon BW, Kingstone K, Satsangi J, Arnott ID, Lees CW.

J Crohns Colitis. 2015 Jan;9(1):41-9. doi: 10.1016/j.crohns.2014.07.005.

44.

Editorial: Early corticosteroids in ulcerative colitis.

Kennedy NA, Satsangi J.

Aliment Pharmacol Ther. 2014 Sep;40(6):727. doi: 10.1111/apt.12879. No abstract available.

45.

Dietary manipulation of oncogenic microRNA expression in human rectal mucosa: a randomized trial.

Humphreys KJ, Conlon MA, Young GP, Topping DL, Hu Y, Winter JM, Bird AR, Cobiac L, Kennedy NA, Michael MZ, Le Leu RK.

Cancer Prev Res (Phila). 2014 Aug;7(8):786-95. doi: 10.1158/1940-6207.CAPR-14-0053.

46.
47.

The role of glycosylation in IBD.

Theodoratou E, Campbell H, Ventham NT, Kolarich D, Pučić-Baković M, Zoldoš V, Fernandes D, Pemberton IK, Rudan I, Kennedy NA, Wuhrer M, Nimmo E, Annese V, McGovern DP, Satsangi J, Lauc G.

Nat Rev Gastroenterol Hepatol. 2014 Oct;11(10):588-600. doi: 10.1038/nrgastro.2014.78. Epub 2014 Jun 10. Review.

PMID:
24912389
48.

Comparison of mortality following hospitalisation for ulcerative colitis in Scotland between 1998-2000 and 2007-2009.

Ventham NT, Kennedy NA, Duffy A, Clark DN, Crowe AM, Knight AD, Nicholls RJ, Satsangi J.

Aliment Pharmacol Ther. 2014 Jun;39(12):1387-97. doi: 10.1111/apt.12750. Epub 2014 Apr 20.

49.

Systematic review: The use of thiopurines or anti-TNF in post-operative Crohn's disease maintenance--progress and prospects.

Jones GR, Kennedy NA, Lees CW, Arnott ID, Satsangi J.

Aliment Pharmacol Ther. 2014 Jun;39(11):1253-65. doi: 10.1111/apt.12743. Epub 2014 Apr 16. Review.

50.

The impact of different DNA extraction kits and laboratories upon the assessment of human gut microbiota composition by 16S rRNA gene sequencing.

Kennedy NA, Walker AW, Berry SH, Duncan SH, Farquarson FM, Louis P, Thomson JM; UK IBD Genetics Consortium, Satsangi J, Flint HJ, Parkhill J, Lees CW, Hold GL.

PLoS One. 2014 Feb 24;9(2):e88982. doi: 10.1371/journal.pone.0088982. eCollection 2014.

Supplemental Content

Loading ...
Support Center